Let’s make a deal, Merck (NYSE: MRK) to acquire Cidara for $9.2 billion
Let’s make a deal, Merck (NYSE: MRK) to acquire Cidara for $9.2 billion Merck (NYSE: MRK) announced it will acquire Cidara Therapeutics (CDTX) for $221.50 per share in cash, valuing the transaction at approximately $9.2 billion. The acquisition centers on...
IBM unveils quantum Nighthawk processor targeting advantage by 2026
IBM unveils quantum Nighthawk processor targeting advantage by 2026 IBM (NYSE: IBM) announced new quantum computing developments at its Quantum Developer Conference, including the IBM Quantum Nighthawk processor and progress toward fault-tolerant quantum computing by...
The verdict is in; Court denies injunction blocking GTCR acquisition in favor of Surmodics (NASDAQ:SRDX)
The verdict is in; Court denies injunction blocking GTCR acquisition in favor of Surmodics (NASDAQ:SRDX) Surmodics Inc. (NASDAQ:SRDX) stock surged 50% after a U.S. District Court denied the Federal Trade Commission’s request for a preliminary injunction...
Let’s make a deal, Revvity (NYSE: RVTY) to acquire ACD/Labs
Let’s make a deal, Revvity (NYSE: RVTY) to acquire ACD/Labs Revvity, Inc. (NYSE: RVTY) has entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software solutions for pharmaceutical and material sciences markets, according to a...
